A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial

European Neuropsychopharmacology

Volumn 21, Issue 3, 2011, Pages 221-229

  Mathew, Sanjay J ^a,e   Vythilingam, Meena ^b   Murrough, James W ^a   Zarate, Carlos A ^b   Feder, Adriana ^a   Luckenbaugh, David A ^b   Kinkead, Becky ^c   Parides, Michael K ^a   Trist, David G ^d   Bani, Massimo S ^d   Bettica, Paolo U ^d   Ratti, Emiliangelo M ^d   Charney, Dennis S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GSK   (Italy)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trial; NK1; PTSD; Randomized; Substance P

Indexed keywords

PLACEBO; VOFOPITANT;

ADULT; ANOREXIA; ARTICLE; CEREBROSPINAL FLUID; CHRONIC DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL MODEL; FATIGUE; FEMALE; HEADACHE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, NEUROKININ-1; STRESS DISORDERS, POST-TRAUMATIC; SUBSTANCE P; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251640951     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.11.012     Document Type: Article

References (33)

1. Benedek D.M., Friedman M.J., Zatzick D., Ursano R.J. Practice guideline for the treatment of patients with acute stress disorder and postraumatic stress disorder. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders 2004.
2. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., et al. The development of a Clinician-Administered PTSD Scale. J. Trauma. Stress 1995, 8:75-90.
3. Committee on Treatment of Posttraumatic Stress Disorder (Institute of Medicine) Treatment of Posttraumatic Stress Disorder: an Assessment of the Evidence 2007, National Academies Press, Washington, DC.
4. Davidson J.R.T. Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson trauma scale, clinical global impressions and the Clinician-Administered PTSD Scale. Int. Clin. Psychopharmacol. 2004, 19:85-87.
5. Davidson J.R., Book S.W., Colket J.T., Tupler L.A., et al. Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol. Med. 1997, 27:153-160.
6. Davidson J.R., Weisler R.H., Butterfield M.I., Casat C.D., et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol. Psychiatry 2003, 53:188-191.
7. Ebner K., Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006, 31:251-272.
8. Ebner K., Rupniak N.M.J., Saria A., Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. USA 2004, 101:4280-4285.
9. Friedman M.J., Marmar C.R., Baker D.G., Sikes C.R. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J. Clin. Psychiatry 2008, 68:711-720.
10. Fujimura Y., Yasuno F., Farris A., Liow J.-S., et al. Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol. Psychiatry 2009, 66:94-97.
11. Furmark T., Appel L., Michelgard A., Wahlstedt K., et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 2005, 58:132-142.
12. George D.T., Gilman J., Hersh J., Thorsell A., et al. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008, 319:1536-1539.
13. Geracioti T.D., Carpenter L.L., Owens M.J., Baker D.G., et al. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am. J. Psychiatry 2006, 63:637-643.
14. Gobert A., Brocco M., Dekeyne A., Di Cara B., et al. Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization. Neuropsychopharmacology 2009, 34:1039-1056.
15. Gray M.J., Litz B.T., Hsu J.L., Lombardo T.W. Psychometric properties of the life events checklist. Assessment 2004, 11:330-341.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338 1976, 218-222. US Department of Health, Education, and Welfare, Washington, DC.
17. Heldt S.A., Davis M., Ratti E., Corsi M., et al. Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils. Behav. Pharmacol. 2009, 20(7):584-595.
18. Hietala J., Nyman M.J., Eskola O., Laakso A., et al. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol. Imag. Biol. 2005, 7:262-272.
19. Holmes A., Heilig M., Rupniak N.M.J., Steckler T., Gabriel G. Investigation of the metabolism of substance P at the blood-brain barrier using LC-MS/MS. Trends Pharmacol. Sci. 2003, 24:580-588.
20. Keller M., Montgomery S., Ball W., Morrison M., et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 2006, 59:216-223.
21. Kramer M.S., Winokur A., Kelsey J., Preskorn S.H., et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004, 29:385-392.
22. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
23. Mathew S.J., Hoffman E.J., Charney D.S. Pharmacotherapy of anxiety disorders. Neurobiology of Mental Illness 2009, 731-754. Oxford University Press, New York. 3rd Edition. D.S. Charney, E.J. Nestler (Eds.).
24. Michelgard A., Appel L., Pissiota A., Frans O., et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol. Psychiatry 2007, 61:1002-1006.
25. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
26. Morgan C.A., Grillon C., Southwick S.M., Davis M., Charney D.S. Fear-potentiated startle in posttraumatic stress disorder. Biol. Psychiatry 1995, 38:378-385.
27. Nakaya Y., Kaneko T., Shigemoto R., Nakanishi S., Mizuno N. Immunohistochemical localization of substance P receptor in the ventral nervous system of the adult rat. J. Comp. Neurol. 1994, 347:249-274.
28. National Institute for Clinical Excellence (NICE) Post-traumatic Stress Disorder: the Management of PTSD in Adults and Children in Primary and Secondary Care 2005, Gaskell and the British Psychological Society, London. http://www.nice.org.uk/pdf/CG026NICEguideline.pdf.
29. Santarelli L., Gobbi G., Debs P.C., Sibille E.L., et al. Genetic and pharmacological distribution of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. USA 2001, 984:1912-1917.
30. Sheehan D.V., Harnett-Sheehan K., Raj B.A. The measurement of disability. Int. Clin. Psychopharmacol. 1996, 11:89-95.
31. Stein D.J., Ipser J.C., Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev. 2006, 25(1):CD002795. Jan.
32. Varty G.B., Cohen-Williams M.E., Morgan C.A., Pylak U., et al. The gerbil elevated plus maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 2002, 27:371-379.
33. Zohar J., Amital D., Miodownik C., Kotler M., et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J. Clin. Psychopharmacol. 2002, 22:190-195.